Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms Clinical research trials and The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms. The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms clinical trial. Human subjects often obtain the finest healthcare possible for their The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.

Home > "T" Clinical Trials Conditions > The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms

The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms



The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms

For Condition: Liver Neoplasm
Status: Recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: The Radiofrequency Interstitial Tissue Ablation (RITA) unit and the Radionics CC-1 Cosman Coagulator system, and LeVeen electrodes and RF 2000 generator of the RadioTherapeutics RF Ablation System are FDA approved devices for the treatment of soft tissue. They use a modification of the standard surgical electrocautery that uses heat to destroy tissue. They have incorporated several improvements including multi-tipped cautery needles for the treatment of a larger volume of tissue as well as thermistors built into the tips which allow for accurate control of tissue temperature. There is already a large experience with these devices for the treatment of hepatic neoplasms. This protocol is designed to allow us to gain experience using these devices as well as to evaluate the use of various imaging modalities to determine tissue responses.
Details: The Radiofrequency Interstitial Tissue Ablation (RITA) unit, the Radionics CC-1 Cosman Coagulator system, and LeVeen electrodes and RF 2000 generator of the RadioTherapeutics RF Ablation System are FDA approved devices for the treatment of soft tissue. They use a modification of the standard surgical electrocautery that uses heat to destroy tissue. They have incorporated several improvements including multi-tipped cautery needles for the treatment of a larger volume of tissue as well as thermistors built into the tips which allow for accurate control of tissue temperature. There is already a large experience with these devices for the treatment of hepatic neoplasms. This protocol is designed to allow us to gain experience using these devices as well as to evaluate the use of various imaging modalities to determine tissue responses.
Eligibility:
Study Type:  Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Patients with either primary or metastatic liver lesions who are not candidates for surgical resection either due to tumor histology, previous surgery, concomitant medical conditions or multi-site disease. Biopsy proven evidence of cancer. Patients with 6 or fewer lesions and with no single lesion greater than 7 cm in maximum diameter. Age greater than or equal to 18 years. Patients must be willing to return to NIH for their imaging scans. Patient must be able to sign informed consent. Life expectancy greater than or equal to 3 months. ECOG performance status 0-2. Patients with extrahepatic disease in addition to their hepatic metastases are eligible and may receive systemic therapy for their extrahepatic disease. EXCLUSION CRITERIA: Patients who are candidates for complete surgical resection. Pregnancy or breast-feeding. A negative pregnancy test (urine or serum) is required prior to enrollment. Known uncontrollable serious reactions such as anaphylaxis, to the contrast agents used in this study. Patients with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices. PT or PTT greater than 1.5X control (except in patients who are therapeutically anticoagulated for non-related medical conditions such as atrial fibrillation). Platelet count less than 50,000. Total bilirubin greater than 3.0. Serum creatinine greater than 2.5. Patients who weigh greater than or equal to 136 kg (weight limit for the PET scanner table). Patients with uncontrolled glucose due to diabetes may be studied, but will be evaluated separately.
Total Enrollment: 58

Location and Contact Information:

National Cancer Institute (NCI) *Recruiting*
Bethesda,  Maryland,  20892
United States
Recruiting Clinical  Support Center/NCI 1-888-624-1937


Additional Information:
Study ID Numbers:  990025;  99-C-0025
Study Start Date: December 23, 1998
Record last reviewed: December 1, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001795

Other Liver Neoplasm Studies:
1. A Phase I Study of Isolated Hepatic Perfusion with Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver

2. Liver Perfusion of Melphalan in Inoperable Liver Cancer

3. A Phase II Study of Isolated Hepatic Perfusion (IHP) with Melphalan Followed by Postoperative Hepatic Arterial Chemotherapy Infusion for Metastatic Unresectable Colorectal Cancers of the Liver

4. The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms

5. Temozolomide and O6-Benzylguanine for Treating Childhood Cancers

Related Studies:

Other Liver Neoplasm Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials

The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms
Modify your Search

  Other Liver Neoplasm Clinical Trials
  Other Maryland Clinical Trials
  Other Bethesda Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103